Project Grant R21NS128212
Award Date 9/1/24
Completion Date 8/31/26
Dollars Obligated $430K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Jacksonville, FL 32224, USA
Similar Awards
- This Project Grant award of $652,751 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports research to engineer antibody drug conjugates (ADCs) designed to enhance the therapeutic window for treating glioblastoma (GBM) and other central nervous system cancers. The research, conducted by the Mayo Clinic, aims to leverage key findings from prior preclinical studies...
- This Project Grant award of $687,279 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports research to uncover the effects of standard-of-care therapy on immune and neoplastic cell population dynamics in pre-clinical mouse models of glioblastoma (GBM) and analysis of human GBM samples. The goal is to identify tumor microenvironment areas of therapeutic...
- The National Cancer Institute (NCI) awarded a $305,031 Project Grant to Round Table Research, Inc. under the Cancer Treatment Research program (CFDA 93.395) to advance extracellular vesicle (EV) therapy for the treatment of glioblastoma (GBM), an aggressive form of brain cancer. The funded project, conducted in collaboration with researchers at the University of North Carolina-Chapel Hill, seeks to develop engineered tumoricidal EVs derived from induced neural stem cells (iNSCs) as a promising...
- This $155,695 Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), supports research at Southern Utah University (SUU) to develop enhanced glioblastoma therapy using engineered extracellular vesicles. The 4-year project, starting on Sep 5, 2025, aims to: 1) determine the ability of bovine milk-derived extracellular vesicles modified with the PEP-1-PHOR21 targeting peptide to cross the...
- This $638,697 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program supports research by the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University (CCLCM) to investigate the role of the SMARCA5 protein in the development and progression of glioblastoma, an aggressive type of brain cancer. The goal of the research is...
- This Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) provides $402,401 to Mayo Clinic Jacksonville (A Nonprofit Corporation) to evaluate the role of SPAK and OSR1 kinases in glioblastoma (GBM) chemotherapy resistance. The 2-year project, running from July 2024 to June 2026, aims to assess if these stress-sensing kinases serve as a resistance mechanism to standard-of-care chemoradiotherapy for GBM, the most deadly brain cancer. The research...
- This $452,375 federal Project Grant awarded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) supports research investigating the role of nuclear mechano-transduction in regulating gene expression and shaping the spatial landscape in glioblastoma (GBM). The 2-year research project, running from August 2025 to July 2027, will be conducted by The Trustees of Columbia...
- This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program will support research on a novel signaling axis involving the protein connexin 43 (CX43) and its role in regulating cancer stem cells in glioblastoma, the most common and deadly form of brain cancer. The $161,000 award to the Cleveland Clinic Lerner College of Medicine of Case Western Reserve...
- The National Institute of Neurological Disorders and Stroke (NINDS), through its Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853), awarded a $420,251 Project Grant to Brigham & Women's Hospital Inc. on May 6, 2025. The grant supports the development of an encapsulated cell-based oncolytic virus therapy for the treatment of glioblastoma (GBM), the most lethal primary brain tumor. The research aims to enhance the therapeutic efficacy of engineered...
- This $442,750 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program supports research to induce and image extrachromosomal DNA (ecDNA) in human glioblastoma cells. The primary goals are to determine if EGFR ecDNA causally fuels glioblastoma tumorigenesis, elucidate how centromere-less ecDNA propagates to daughter cells during mitosis, and...